Alzheimer's Disease: Translating Neurochemical Insights Into Clinical Benefits

Click to enlarge page

Dr. Changiz Geula reviewed recent evidence that updates the "cholinergic hypothesis" and provides insights into the clinical efficacy of cholinesterase (ChE) inhibitors. Alzheimer’s disease is widely acknowledged to involve characteristic morphologic brain lesions and neurochemical changes particularly within cortical cholinergic systems. Pathologic lesions in the brains of Alzheimer’s disease patients at postmortem consist of extracellular plaques formed primarily of the amyloid- protein and intraneuronal neurofibrillary tangles, stated Dr. Geula.